In this investigation, we addressed the question of whether an alternative therapy called enhanced external counterpulsation (EECP) that is a noninvasive, FDA-approved therapy for angina refractory to standard treatments may achieve its clinical benefits through mobilization of particular subpopulations of CD34+ stem cells [5]. The gene discussed is CD34; the disease is angina pectoris.